{"nctId":"NCT00223704","briefTitle":"Bradykinin Receptor Antagonism During Cardiopulmonary Bypass","startDateStruct":{"date":"2006-05"},"conditions":["Cardiopulmonary Bypass","Inflammation","Fibrinolysis","Surgery"],"count":150,"armGroups":[{"label":"HOE 140","type":"EXPERIMENTAL","interventionNames":["Drug: HOE 140"]},{"label":"Aminocaproic Acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aminocaproic Acid"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"HOE 140","otherNames":["Icatibant"]},{"name":"Aminocaproic Acid","otherNames":["Amicar","EACA"]},{"name":"Placebo","otherNames":["Placebo/Normal Saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subjects, 18 to 80 years of age, scheduled for elective CABG requiring CPB\n2. For female subjects, the following conditions must be met:\n\npostmenopausal for at least 1 year, or status-post surgical sterilization, or if of childbearing potential, utilizing adequate birth control and willing to undergo urine beta-hcg testing prior to drug treatment and on every study day\n\nExclusion Criteria:\n\n1. Evidence of coagulopathy (INR greater than 1.7 without warfarin therapy)\n2. Preoperative hematocrit less than 30%\n3. Preoperative platelet count less than 100X109ml-1\n4. GPIIb/IIIa antagonist within 48 hours of surgery\n5. Emergency surgery\n6. Impaired renal function (serum creatinine \\>1.6 mg/dl)\n7. Pregnancy\n8. Breast-feeding\n9. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult\n10. History of alcohol or drug abuse\n11. Treatment with any investigational drug in the 1 month preceding the study\n12. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study\n13. Inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Allogenic Blood Product Transfusion Risk","description":"Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"56.8","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null},{"groupId":"OG001","value":"48.6","spread":null},{"groupId":"OG002","value":"47.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"24.3","spread":null},{"groupId":"OG002","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"16.2","spread":null},{"groupId":"OG002","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Units of Packed Red Blood Cells Transfused During Hospitalization","description":"Units of Packed Red Blood Cells Transfused","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":"0.61"},{"groupId":"OG001","value":"1.41","spread":"0.30"},{"groupId":"OG002","value":"1.45","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Units of Plasma Transfused During Hospitalization","description":"Units of plasma transfused","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"0.37"},{"groupId":"OG001","value":"0.68","spread":"0.25"},{"groupId":"OG002","value":"0.82","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Inflammatory Response as Measured by Interleukin-6","description":"Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.98","spread":"0.77"},{"groupId":"OG001","value":"6.58","spread":"1.50"},{"groupId":"OG002","value":"4.80","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":"17.49"},{"groupId":"OG001","value":"64.65","spread":"12.24"},{"groupId":"OG002","value":"142.02","spread":"85.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118.8","spread":"19.15"},{"groupId":"OG001","value":"161.91","spread":"28.19"},{"groupId":"OG002","value":"166.27","spread":"49.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"201.5","spread":"95.29"},{"groupId":"OG001","value":"122.88","spread":"19.54"},{"groupId":"OG002","value":"86.54","spread":"15.84"}]}]}]},{"type":"SECONDARY","title":"Fibrinolytic Response as Measured by D-dimer","description":"D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":"12.0"},{"groupId":"OG001","value":"103.0","spread":"18.8"},{"groupId":"OG002","value":"88.1","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150.6","spread":"17.5"},{"groupId":"OG001","value":"131.9","spread":"19.7"},{"groupId":"OG002","value":"209.0","spread":"49.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"287.6","spread":"51.1"},{"groupId":"OG001","value":"154.3","spread":"24.7"},{"groupId":"OG002","value":"363.3","spread":"74.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"589.8","spread":"104.5"},{"groupId":"OG001","value":"168.9","spread":"22.4"},{"groupId":"OG002","value":"858.5","spread":"182.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"390.4","spread":"73.2"},{"groupId":"OG001","value":"269.5","spread":"51.3"},{"groupId":"OG002","value":"337.3","spread":"36.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":38},"commonTop":["New onset postoperative atrial fibrillation","Acute kidney injury","Prolonged Mechanical Ventilation (>24 hours)","Placement of permanent pacemaker"]}}}